Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    In-Person

    Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction in Alzheimer's Disease

    What is this Study about?

    Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.

    Eligibility Criteria

    Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.

    Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.

    Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.

    Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.

    Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.

    Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.

    Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.

    Have not undergone any significant head trauma or surgery in the past 6 months.

    Are not pregnant or planning to become pregnant during the duration of the study.

    Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.

    Ability to speak English and French

    Recruitment End Date

    Find Out More
  • Observational Study
    Ontario

    Development of a CAregiver Reported outcome measure for Dementia (CARED)

    What is this Study about?

    Caregivers of people living with dementia have direct experience of how the dementia is progressing. They are essential in evaluating the real-world benefits of treatment and making decisions to keep the person at home or consider different levels of care. The aim of this study is to develop a new CAregiver REported and weighted Dementia outcome measure (CARED).

    Eligibility Criteria

    You are eligible to participate if you are:

    • A caregiver, at least 18 years of age, and supporting a friend, partner, or family member with a diagnosis of dementia living in the community.

    Recruitment End Date

    Find Out More